Lung Cancer New Generation Target Drug Laura Tini: Significantly Improves the Progressless Lifetime of ALK-Positive Lung Cancer.

Pfizer announced positive results from the mid-term efficacy analysis of CROWN in Phase III clinical studies, and Larlatinib achieved a significant improvement in patients with progression-free survival (PFS) in patients with late-stage degenerative lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) compared to crizotinib.
: AACR Annual Meeting 2018 lorlatinib and crizotinib are consistent with previously observed in clinical trials.
the results of THECROWN will be presented to the upcoming Medical Assembly.
lung cancer is the leading cause of cancer-related deaths worldwide, with NSCLC accounting for about 80-85% of lung cancer and ALK positive accounting for about 3-5% of NSCLC cases.
, patients with advanced NSCLC had a five-year survival rate of only 5% prior to targeted treatment and immunotherapy.
About Laura typini LORBRENA is a new generation of tyrosine kinase inhibitors (TKI), which show high activity in preclinical lung cancer models with ALK chromosome rearrology and are specifically developed to resist tumors that are resistant to other ALK inhibitors and have strong blood-brain barrier permeability.
2018, the U.S. Food and Drug Administration (FDA) approved LORBRENA: for the treatment of ALK-positive NSCLC patients who metastasization after treatment with quetonib or at least one other ALK inhibitor;
About THEN study CROWN is a Phase 3 randomized, open-label, parallel arm study in which 296 patients with advanced ALK-positive non-small cell lung cancer who had not previously been treated were randomly assigned to LORBRENA single-drug or XALKORI single-drug therapy at 1:1.
end point of the CROWN trial was improved patient progression-free survival (PFS).
secondary endpoints include overall survival, objective response (OR), intracranial OR (IC-OR), IC progression time, reaction duration (DR), IC-DR, tumor response time (TTR), IC-TTR.
.